• Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD).  
• Under the agreement, Fresenius Kabi will exclusively commercialize SCD’s aflibercept biosimilar candidate in the U.S. and several countries in Latin America.  
• Aflibercept is used to treat a range of ophthalmic disorders, including wet age-related macular degeneration.   

Under the agreement, Fresenius Kabi will commercialize the proposed aflibercept biosimilar, a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein, in the US, Brazil, Argentina, Chile, Paraguay, Colombia, and Mexico after successful approval by respective health agencies. SCD is responsible for the development, manufacturing, and supply of the drug.

Fresenius Kabi is an operating company of Fresenius that specializes in (bio)pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions.

SCD is based in South Korea and specializes in developing generics and biosimilars for global markets.
 
Aflibercept is a proposed biosimilar referencing Eylea®, an anti-VEGF for the treatment of ophthalmic conditions such as wet age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). Eylea is commercialized by Regeneron in the US and by Bayer in other countries.

“With the commercialization of the aflibercept biosimilar, we are broadening our product portfolio with a treatment option for ophthalmic diseases. In alignment with our #FutureFresenius strategy, this marks another significant milestone for Fresenius Kabi in fulfilling our strategic objective of enhancing access to biosimilars for patients globally,” said Dr. Sang-Jin Pak, Fresenius Kabi’s President of Business Unit Biopharma.

"We are thrilled to have finalized this agreement and are eager to move forward with the commercialization of our aflibercept biosimilar candidate upon approval. The combination of SCD’s specialized expertise in ophthalmology and Fresenius Kabi’s global commercial strength creates a robust foundation to support our shared objective of improving patient access to more affordable treatment options in ophthalmology," says Mr. Chun In Seok, Chief Executive Officer at SCD.

*Eylea® is a registered trademark of Regeneron.

• Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD). 
• Under the agreement, Fresenius Kabi will exclusively commercialize SCD’s aflibercept biosimilar candidate in the U.S. and several countries in Latin America.  
• Aflibercept is used to treat a range of ophthalmic disorders, including wet age-related macular degeneration.   

Under the agreement, Fresenius Kabi will commercialize the proposed aflibercept biosimilar, a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein, in the US, Brazil, Argentina, Chile, Paraguay, Colombia, and Mexico after successful approval by respective health agencies. SCD is responsible for the development, manufacturing, and supply of the drug.

Fresenius Kabi is an operating company of Fresenius that specializes in (bio)pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions.

SCD is based in South Korea and specializes in developing generics and biosimilars for global markets.
 
Aflibercept is a proposed biosimilar referencing Eylea®, an anti-VEGF for the treatment of ophthalmic conditions such as wet age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). Eylea is commercialized by Regeneron in the US and by Bayer in other countries.

“With the commercialization of the aflibercept biosimilar, we are broadening our product portfolio with a treatment option for ophthalmic diseases. In alignment with our #FutureFresenius strategy, this marks another significant milestone for Fresenius Kabi in fulfilling our strategic objective of enhancing access to biosimilars for patients globally,” said Dr. Sang-Jin Pak, Fresenius Kabi’s President of Business Unit Biopharma.

"We are thrilled to have finalized this agreement and are eager to move forward with the commercialization of our aflibercept biosimilar candidate upon approval. The combination of SCD’s specialized expertise in ophthalmology and Fresenius Kabi’s global commercial strength creates a robust foundation to support our shared objective of improving patient access to more affordable treatment options in ophthalmology," says Mr. Chun In Seok, Chief Executive Officer at SCD.

*Eylea® is a registered trademark of Regeneron.

As of January 1, 2025, Fresenius will operate the hospital services business, previously owned by VAMED, as a Fresenius subsidiary under the name Fresenius Health Services (FHS). Fresenius had already announced the step in May 2024. Enrico Jensch, previously Chief Operating Officer of Helios Germany, will be CEO of FHS. At the Fresenius Management Board level, Robert Möller will be responsible for FHS.

Fresenius Health Services supports healthcare facilities in operating an efficient and needs-based technical infrastructure. The company offers comprehensive services and advice on medical technology, operating technology and sterile supply.

Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a prescription medicine used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock; for emergency treatment of allergic reactions including anaphylaxis and for induction and maintenance of mydriasis during intraocular surgery.

In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion in recent years to expand and update its U.S. pharmaceutical production as well as distribution facilities. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List.
 

Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a prescription medicine used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock; for emergency treatment of allergic reactions including anaphylaxis and for induction and maintenance of mydriasis during intraocular surgery.

In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion in recent years to expand and update its U.S. pharmaceutical production as well as distribution facilities. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List.
 

Solutions for a strong infrastructure in healthcare facilities

Fresenius Health Services offers comprehensive services and consulting for the technical infrastructure of healthcare facilities. This includes biomedical engineering, building services engineering and medical instrument decontamination and sterilisation services as well as the digitalisation of processes.

Together with our customers, we develop sustainable concepts for efficient and needs-based technical operations, which we ensure in the long term with our services. This enables doctors and nursing staff to make the best possible efforts to help their patients recover quickly and successfully.

Fresenius Health Services operates in nine European countries, where we support more than 800 healthcare facilities with around 4,400 employees.

Our unique selling points

• Specialised: With our comprehensive expertise in all processes in medicine and care, we provide healthcare facilities with an optimally supportive technical and digital infrastructure.
• Manufacturer-neutral: We consistently align the technical equipment and processes with specific medical requirements.
• Practical experience: Our equipment and maintenance concepts are based on our many years of practical experience. We also implement them efficiently.
• Data-based: Thanks to our many years of experience in operation, we have extensive data on the performance and operating costs of thousands of devices and systems. This enables us to optimise equipment fleets to meet specific requirements and develop them in a future-proof manner.
• Innovative: Thanks to our in-depth market knowledge and contacts, we can adapt innovations in the field of AI and digitalisation for hospital operations and integrate them into processes to add value.

 

Our aim

• By providing an efficient technical infrastructure, we ensure that doctors and nursing staff can do their utmost to help patients recover quickly and successfully.
• We assume full responsibility for the complex technical operation of healthcare facilities and thus relieve their management of the associated tasks and duties – so that they can concentrate fully on their core business of medicine and care.
• We offer comprehensive and up-to-date expertise in technical solutions and digital innovations. Together with our knowledge of medical and nursing processes, we enable the future-proof operation of healthcare facilities.
• We offer best-practice solutions that have been developed and proven in practice – with more than 700 customers in Europe.
• We work for healthcare facilities of various sizes, care levels and organisations. Accordingly, we are just as familiar with the requirements and needs of a small district hospital as we are with those of a large private clinic operator.

 

 

Our services

Fresenius, via its operating company Fresenius Kabi, and Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, have entered an agreement to provide the integration of the IRO® platform with Fresenius Kabi’s upstream and downstream processing technologies. The successful integration of these leading technology platforms provides a streamlined, closed workflow for cell therapy manufacturing that can reduce process steps, tube- and bag-based transfers, and operator touch time. This collaboration underscores Ori Biotech and Fresenius Kabi’s shared commitment to driving innovation and developing widespread patient access to life-saving cell and gene therapies. All to help bring cell and gene therapies to market faster and more efficiently, in line with #FutureFresenius.

Fresenius, via its operating company Fresenius Kabi, and Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, have entered an agreement to provide the integration of the IRO® platform with Fresenius Kabi’s upstream and downstream processing technologies. The successful integration of these leading technology platforms provides a streamlined, closed workflow for cell therapy manufacturing that can reduce process steps, tube- and bag-based transfers, and operator touch time. This collaboration underscores Ori Biotech and Fresenius Kabi’s shared commitment to driving innovation and developing widespread patient access to life-saving cell and gene therapies. All to help bring cell and gene therapies to market faster and more efficiently, in line with #FutureFresenius.